Literature DB >> 6330841

Elimination of poliomyelitis in Finland.

K Lapinleimu.   

Abstract

In Finland paralytic poliomyelitis has disappeared after immunization programs carried out exclusively with inactivated poliovirus vaccine (IPV). A sharp decrease in the number of patients with poliomyelitis occurred after mass vaccination in 1960-1961, when 51% of the population had received the complete primary vaccination. Immunity is maintained by continuous vaccination of infants, whose vaccination rate is close to 98%. Intensive poliovirus surveillance in 1972-1974 revealed that dissemination of the virus has also virtually ceased. Serologic surveys indicate that greater than or equal to 90% of individuals older than 15 years of age possess antibodies to all viral types, but in the younger age groups the proportion with antibodies to types 1 and 3 is lower, a finding that is alarming, especially in the case of type 3. Revaccination of seronegative children and conscripts has induced rapid booster-like responses, indicating that fully vaccinated individuals, although without demonstrable antibodies, are protected against poliomyelitis. The new, improved IPV developed in Holland induces satisfactory antibody titers in all vaccinees, with two injections--or perhaps even one--leading to long-lasting immunity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6330841     DOI: 10.1093/clinids/6.supplement_2.s457

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  11 in total

1.  Intestinal trypsin can significantly modify antigenic properties of polioviruses: implications for the use of inactivated poliovirus vaccine.

Authors:  M Roivainen; T Hovi
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

Review 2.  Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Konstantin M Chumakov; Neal A Halsey; Tapani Hovi; Philip D Minor; John F Modlin; Peter A Patriarca; Roland W Sutter; Peter F Wright; Steven G F Wassilak; Stephen L Cochi; Jong-Hoon Kim; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-28       Impact factor: 4.000

3.  Inadequacy of mucosal IgM antibodies in selective IgA deficiency: excretion of attenuated polio viruses is prolonged.

Authors:  E Savilahti; T Klemola; B Carlsson; L Mellander; M Stenvik; T Hovi
Journal:  J Clin Immunol       Date:  1988-03       Impact factor: 8.317

4.  Cleavage of VP1 and modification of antigenic site 1 of type 2 polioviruses by intestinal trypsin.

Authors:  M Roivainen; T Hovi
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

5.  Proportions of immunoglobulin isotypes in paralytic poliomyelitis and after vaccination.

Authors:  I Julkunen; P Ukkonen; M Stenvik; T Hovi; L Renkonen; O Mäkelä
Journal:  J Clin Immunol       Date:  1987-07       Impact factor: 8.317

6.  Polio immunization policy in the United States: a new challenge for a new generation.

Authors:  D Salk
Journal:  Am J Public Health       Date:  1988-03       Impact factor: 9.308

7.  Were there long-term economic effects of exposure to polio vaccination? An analysis of migrants to Sweden 1946-2003.

Authors:  Luis Serratos-Sotelo
Journal:  SSM Popul Health       Date:  2020-05-20

Review 8.  Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.

Authors:  Radboud J Duintjer Tebbens; Kimberly M Thompson
Journal:  Expert Rev Vaccines       Date:  2018-08-09       Impact factor: 5.217

9.  Poliovirus antibody levels and lameness among individuals in three regions of Ghana.

Authors:  Joseph Kwadwo Larbi Opare; John Kofi Odoom; Patricia Akweongo; Edwin Andrew Afari; Matilda Pappoe
Journal:  Hum Vaccin Immunother       Date:  2019-07-25       Impact factor: 3.452

Review 10.  Eradicating poliomyelitis: India's journey from hyperendemic to polio-free status.

Authors:  T Jacob John; Vipin M Vashishtha
Journal:  Indian J Med Res       Date:  2013-05       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.